Contribution of Selected Gene Mutations to Resistance in Clinical Isolates of Vancomycin-Intermediate Staphylococcus aureus

ABSTRACT Infections with vancomycin-intermediate Staphylococcus aureus (VISA) have been associated with vancomycin treatment failures and poor clinical outcomes. Routine identification of clinical isolates with increased vancomycin MICs remains challenging, and no molecular marker exists to aid in diagnosis of VISA strains. We tested vancomycin susceptibilities by using microscan, Etest, and population analyses in a collection of putative VISA, methicillin-resistant S. aureus, and methicillin-sensitive S. aureus (VSSA) infectious isolates from community- or hospital-associated S. aureus infections (n = 77) and identified 22 VISA and 9 heterogeneous VISA (hVISA) isolates. Sequencing of VISA candidate loci vraS, vraR, yvqF, graR, graS, walR, walK, and rpoB revealed a high diversity of nonsynonymous single-nucleotide polymorphisms (SNPs). For vraS, vraR, yvqF, walK, and rpoB, SNPs were more frequently present in VISA and hVISA than in VSSA isolates, whereas mutations in graR, graS, and walR were exclusively detected in VISA isolates. For each of the individual loci, SNPs were only detected in about half of the VISA isolates. All but one VISA isolate had at least one SNP in any of the genes sequenced, and isolates with an MIC of 6 or 8 μg/ml harbored at least 2 SNPs. Overall, increasing vancomycin MICs were paralleled by a higher proportion of isolates with SNPs. Depending on the clonal background, SNPs appeared to preferentially accumulate in vraS and vraR for sequence type 8 (ST8) and in walK and walR for ST5 isolates. Taken together, by comparing VISA, hVISA, and VSSA controls, we observed preferential clustering of SNPs in VISA candidate genes, with an unexpectedly high diversity across these loci. Our results support a polygenetic etiology of VISA.

[1]  Boris M. Hartmann,et al.  Genetic Pathway in Acquisition and Loss of Vancomycin Resistance in a Methicillin Resistant Staphylococcus aureus (MRSA) Strain of Clonal Type USA300 , 2012, PLoS pathogens.

[2]  Torsten Seemann,et al.  Evolution of Multidrug Resistance during Staphylococcus aureus Infection Involves Mutation of the Essential Two Component Regulator WalKR , 2011, PLoS pathogens.

[3]  F. Lowy,et al.  The Environment as an Unrecognized Reservoir for Community-Associated Methicillin Resistant Staphylococcus aureus USA300: A Case-Control Study , 2011, PloS one.

[4]  L. Cui,et al.  Mutation of RNA Polymerase β Subunit (rpoB) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3 , 2011, Antimicrobial Agents and Chemotherapy.

[5]  L. Cui,et al.  walK and clpP Mutations Confer Reduced Vancomycin Susceptibility in Staphylococcus aureus , 2011, Antimicrobial Agents and Chemotherapy.

[6]  L. Cui,et al.  Impact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus , 2011, Journal of Clinical Microbiology.

[7]  A. Gikas,et al.  International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. , 2010, American journal of infection control.

[8]  Paul D. R. Johnson,et al.  Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications , 2010, Clinical Microbiology Reviews.

[9]  M. Rybak,et al.  Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. , 2009, The Journal of antimicrobial chemotherapy.

[10]  L. Cui,et al.  Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[11]  D. Allen,et al.  Genomic Analysis Reveals a Point Mutation in the Two-Component Sensor Gene graS That Leads to Intermediate Vancomycin Resistance in Clinical Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[12]  M. Wootton,et al.  Evaluation of a New Etest Vancomycin-Teicoplanin Strip for Detection of Glycopeptide-Intermediate Staphylococcus aureus (GISA), in Particular, Heterogeneous GISA , 2008, Journal of Clinical Microbiology.

[13]  A. Mellmann,et al.  Characterization of Clonal Relatedness among the Natural Population of Staphylococcus aureus Strains by Using spa Sequence Typing and the BURP (Based upon Repeat Patterns) Algorithm , 2008, Journal of Clinical Microbiology.

[14]  J. Stoye,et al.  Based Upon Repeat Pattern (BURP): an algorithm to characterize the long-term evolution of Staphylococcus aureus populations based on spa polymorphisms , 2007, BMC Microbiology.

[15]  H. Yuzawa,et al.  Mutated Response Regulator graR Is Responsible for Phenotypic Conversion of Staphylococcus aureus from Heterogeneous Vancomycin-Intermediate Resistance to Vancomycin-Intermediate Resistance , 2007, Antimicrobial Agents and Chemotherapy.

[16]  H. de Lencastre,et al.  Multiplex PCR strategy for subtyping the staphylococcal cassette chromosome mec type IV in methicillin-resistant Staphylococcus aureus: 'SCCmec IV multiplex'. , 2007, The Journal of antimicrobial chemotherapy.

[17]  H. de Lencastre,et al.  Update to the Multiplex PCR Strategy for Assignment of mec Element Types in Staphylococcus aureus , 2007, Antimicrobial Agents and Chemotherapy.

[18]  Alexander Tomasz,et al.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing , 2007, Proceedings of the National Academy of Sciences.

[19]  F. Tenover,et al.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Yin,et al.  The VraS/VraR two-component regulatory system required for oxacillin resistance in community-acquired methicillin-resistant Staphylococcus aureus. , 2006, FEMS microbiology letters.

[21]  James G. Johnson,et al.  Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Ward,et al.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Tomasz,et al.  High Level Oxacillin and Vancomycin Resistance and Altered Cell Wall Composition in Staphylococcus aureus Carrying the Staphylococcal mecA and the Enterococcal vanA Gene Complex* , 2004, Journal of Biological Chemistry.

[24]  J. Rothgänger,et al.  Typing of Methicillin-Resistant Staphylococcus aureus in a University Hospital Setting by Using Novel Software for spa Repeat Determination and Database Management , 2003, Journal of Clinical Microbiology.

[25]  A. Tomasz,et al.  Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy , 2003, Journal of Clinical Microbiology.

[26]  G. Eliopoulos,et al.  Accessory Gene Regulator (agr) Locus in Geographically Diverse Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin , 2002, Antimicrobial Agents and Chemotherapy.

[27]  A. MacGowan,et al.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. , 2001, The Journal of antimicrobial chemotherapy.

[28]  C. Martín,et al.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital , 1998, The Lancet.

[29]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[30]  Takahisa Suzuki,et al.  Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. , 2010, The Journal of antimicrobial chemotherapy.

[31]  G. Eliopoulos,et al.  Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[33]  B. Spratt,et al.  Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. , 2000, Journal of clinical microbiology.

[34]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .